Icecure Medical Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
32.0%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$4.5Mnext fiscal year
FY EPS (est.)
-$4.61next fiscal year
Monitoring Framework
Key Performance Indicators
U.S. Commercial Install Base Growth Quarterly7,000.0%Target: Continued expansion following FDA clearance
Global Revenue Growth Rate (Q1 2026 vs Q1 2025) Quarterly2,600.0%Target: High double-digit annual growth
North American Sales Growth Rate (Q1 2026 vs Q1 2025) Quarterly8,400.0%Target: Sustained regional expansion
Watch Items
- ChoICE Trial Post-Market Study Patient EnrollmentTrigger: Commencement of patient enrollment in H2 2026 with at least 80 patients in Year 1Action: Monitor clinical site activation and patient recruitment rates across 30 planned U.S. sites
- Health Canada Class III Amendment Regulatory ApprovalTrigger: Decision on expanded indication for early-stage, low-risk invasive breast cancer in patients aged 60+Action: Track regulatory correspondence and potential approval announcements from Health Canada
- Nasdaq Minimum Bid Price ComplianceTrigger: Maintaining bid price above $1.00 post 1-for-30 reverse share splitAction: Monitor stock trading price and official compliance notifications from Nasdaq
Research as of 19 Jun 2026